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Abstract
Background: Fungal infections represent a serious health problem especially in immunocompromised individuals. Candida albi-
cans is the most common fungi that cause superficial and systemic infections with high mortality rates. Anti-fungal resistance of  
C. albicans may be attributed to its virulence. Biofilm formation and proteolytic activity are major virulence determents that may 
influence both pathogenicity and anti-fungal resistance of  Candida albicans. 
Objective: This work studied the relation between biofilm formation, proteolytic activity and prevalence of  some Sap genes 
with reduced susceptibility of  C. albicans to different anti-fungal agents.
Methods: Fifty three C. albicans strains isolated from patients with systemic infections, identified by germ tube, chromogenic 
agar and confirmed by PCR, were subjected to evaluate their proteolytic activity, the degree of  biofilm production and the 
prevalence of  Sap9 and Sap10 genes. The susceptibility of  the isolates was determined by disk diffusion method against five 
antifungal drugs.
Results and conclusion: Four of  the C. albicans isolates were resistant to 3 anti-fungal drugs, strong biofilm producer, have 
proteolytic activity and contain either Sap9 or Sap10 or both. Conclusively, although anti-fungal resistance among the isolates 
was rare, a relation between the anti-fungal resistance and some major virulence factors was evidently proved in this study.
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Candida infections have a significant rise in morbidity 
and mortality, especially in recent years due to the contin-
uous increase in the number of  immunosuppressive pa-
tients1. Candida albicans is determined as the major human 
pathogen in the genus Candida2. C. albicans is classified as 
commensal fungi that present in` many anatomical sites 
of  the human body3. C. albicans can cause oral and vaginal 
infections as well as systemic diseases4. The rise in the 
incidence of  Candida infections is complicated by the an-
timicrobial resistance and the limited number of  available 
anti-fungal drugs5. 
The ability of  Candida to cause infection depends main-
ly on its intrinsic virulence attributes6. C. albicans cause 
critical problems because it has more virulence factors 
than non-Candida albicans isolates7. C. albicans has several 
virulence factors including phenotyping changes, biofilm 
formation, and production of  harmful substances to 
cells, such as haemolysins, phospholipases and proteases 
as well as the ability to resist hydrogen peroxide8. 
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Among the hydrolytic enzymes that secreted by Candi-
da spp. are the aspartic proteases which represent one of  
the major virulence determinants as they have a potential 
role in pathogenicity through facilitating the invasion and 
counteracting the host defense system9. 
Secreted aspartic proteases (Saps), encoded by a family of  
10 sap genes (sap1–sap10) which have a vital role in vir-
ulence of  C. albicans by degrading host tissue proteins as 
well as adhere to epithelial host tissue10. Saps have a broad 
substrate specificity of  human proteins such as albumin, 
haemoglobin, keratin, collagen, laminin, fibronectin, mu-
cin and almost all immunoglobulins, including immuno-
globulin A, which is resistant to the majority of  bacterial 
proteases11. A correlation between the expansion of  sap 
genes and the transition from commensal to pathogen-
ic microorganisms has been reported12. Non-pathogenic 
Candida spp. usually has fewer genes encoding Sap than 
pathogenic species and this fact was confirmed by gene 
sequencing. However, this rule cannot be applied to spe-
cies such as C. glabrata or C. krusei, which do not possess 
any sap genes12. On the other hand, there is a correlation 
reported between Sap proteinase  production and biofilm 
formation13. 
Biofilms are defined as self-derived extracellular matrix 
that produced by the microbial population attached to 
abiotic surface including biomedical devices or biotic 
surfaces including oral and vaginal mucosa14,15. C. albicans 
present in biofilm structure show a decrease in suscepti-
bility to some anti-fungals as well as a reduction in killing 
by the host immune system16. Sap 9 and Sap10 enzymes 
maintain cell surface integrity of  the Candida cell wall, and 
promote biofilm formation17.  
This study aims to correlate between sap9 and sap10 
prevalence and its role in biofilm formation and drug re-




All the clinical specimens were collected under ethi-
cal standards from different Departments at Mansoura 
University Hospitals, and identified according to Chees-
brough18. Briefly, the specimens were inoculated on Sab-
ouraud dextrose agar (SDA) plates and incubated at 37 °C 
for 24-48 hr. The suspected colonies of  C. albicans were 
examined for their colonial morphology, Gram staining, 
germ tube formation, culture characteristics on Candida 
chromogenic agar (Pronadisa Co., Madrid, Spain) and 
the identification was confirmed by PCR19, The standard 
strain of  Candida albicans (ATCC 10231) was included in 
this study.
Determination of  anti-fungal susceptibility by disk 
diffusion method
Candida albicans isolates were tested for their susceptibility 
to different anti-fungal agents by disk diffusion method 
according to CLSI guideline20. The tested disks that in-
clude; Amphotericin B (AMB, 10µg), Fluconazole (FLU, 
25µg), Voriconazole (VOR, 1µg), Fluorocytosine (5FC, 
1µg), Caspofungin (CASP, 5µg); were obtained from Bio-
analyse, Turkey.
Phenotypic detection of  aspartyl proteinase activity 
in C. albicans isolates
Briefly, Candida isolates were cultured in YEPD medium 
(2% glucose, 1% yeast extract, and 2% Bactopeptone) 
and then they induced to secrete proteinases onto the 
bovine serum albumin (BSA) agar. Filter paper disks, 6 
mm diameter, were dipped into a suspension of  Candida 
culture at a density of  107 cell mL–1 (0.5 McFarland) in 
YEPD medium and applied to BSA agar plate. A maxi-
mum of  4 disks was used for each 9 cm diameter plate. 
The plates were incubated at 28°C for 7 days. The plates 
were observed daily for opacity around the disks, the 
opacity caused by albumin precipitation was observed for 
subsequent clearing due to hydrolysis by the acid protein-
ases of  the fungi. The millimetric zones were evaluated as 
negative (–) for no clearance, positive (+) for mild activity 
(lysis zone of  1-2 mm around the disk), and double-pos-
itive (++) for strong activity (lysis zone of  3-5 mm). The 
standard strain was used as positive controls, and the ex-
periment was performed in triplicate21. 
Genotypic detection of  Sap9 and Sap10 in Candida 
albicans isolates using PCR 
DNA of  Candida albicans was extracted by colo-
ny PCR method22. The primers used for detection  of  
sap9 and sap10 in C. albicans  (SAP9F: 5` ATTTACTC-
CACAGTTTATATCACTGAAGGT3`, SAP9R: 5` 
CCACCAGAACCACCCTCAGTT 3`,  SAP10F: 5` 
CCCGGTATCCAATAGAATCGAA3` and  SAP10R: 
5` TCAGTGAATGTGACGAATTTGAAGA 3`) were 
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purchased from Operon Biotechnologies GmbH Bio-
compus cologne, Germany23. 
DNA samples were amplified in 25     reaction mixture 
containing 2.5 µL DNA, 12.5 µL  my Taq red mix (Bio-
line Co., UK), 1 µL forward primer (10 µL M), 1 µL re-
verse primer (10 µL M) and nuclease free water to 25 µL . 
the cycling conditions include heating at 94°C for 5 min, 
then 35 cycles of  94°C for 10 sec, 59°C for 20 sec and 
72°C for 30 sec and finally heating at 72°C for 3 min. 
The PCR products as well as GeneRuler 50 bp plus DNA 
ladder (Thermo scientific, USA) were separated on 1.5% 
agarose gel, stained with ethidium bromide, visualized by 
UV transilluminator and photographed.
 
Detection of  biofilm formation in Candida albicans iso-
lates 
The biofilm formation was performed as described pre-
viously24. Briefly, a colony from each isolate was obtained 
from the overnight growth on SDA agar plate and inocu-
lated into 5 mL of  Sabouraud broth (SDB). Broths were 
incubated for 18-20 hr at 37°C. Yeast cells were twice 
centrifuged (5000 rpm for 5 min) and washed with 0.5 
mL phosphate buffer saline (PBS). The cells were re-sus-
pended in 1 mL SD broth and adjusted to concentration 
of  107cells/mL. Then, 200 µL  of  each isolate suspen-
sion was inoculated into individual well of  polystyrene 
96-well plates, planktonic cells were discarded through 
three rounds of  washing with 200 µL sterile PBS buffer, 
and the plates dried at room temperature for 45 min. For 
staining, 150 µL of  0.4% Crystal Violet (CV), was added 
to each well, after 45 min, supernatant was discarded be-
fore adding 150 µL of  95% ethanol to dissolve and/or 
elute CV from the biofilm for 45 min. Finally, 100 µL  of  
each well was transferred to a new 96-well microtiter plate 
and the absorbance at 540 nm was determined using a 
microtiter plate reader Synergy HT (BioTek Instruments, 
Winooski, VT, USA). 
For each strain, the mean OD of  four wells was calculat-
ed (ODt) and also cut-off  OD (ODc) was defined as 3 
standard deviations above the mean OD of  the negative 
control. The level of  biofilm production was determined 
as follows: non-biofilm producer (N) ODt ≤ ODc, weak 
biofilm producer (W) ODc < ODt ≤ 2×ODc, moder-
ate biofilm producer (M) 2×ODc < ODt ≤ 4×ODc and 
strong biofilm producer (S) ODt > 4×ODc25. 
Results
Identification of  C. albicans isolates
Fifty three non-duplicate Candida albicans clinical isolates 
were identified in the present study. The isolates were 
identified as Candida albicans by PCR. Meanwhile, 51 iso-
lates gave green colonies of  Candida albicans on Chromo-
genic agar and 45 of  Candida albicans isolates were germ 
tube positive. On the other hand, 8 isolates of  C. albicans 
were germ tube negative (false negative). Among these 
isolates 30 were from the respiratory tract, 17 from uri-
nary tract and 6 were from blood samples. 
 
Susceptibility to anti-fungals
The data presented in table (1), showed the susceptibility 
of  Candida albicans to the different anti-fungal disks. The 
data revealed that, out of  53 Candida albicans isolates five 
(9.4%) isolates were resistant to three anti-fungal drugs. 
Approximately, fluconazole and voriconazole show 9.4%, 
11.3% resistance while 5 fluorocytosine show 100% resis-
tance. On the other hand, both caspofungin and ampho-
tericin B show no resistance.
Table 1  
 
  
Antifungals   
Number and percentage of C. albicans isolates (n=53) 
R I S 
N % N % N % 
FLU 5 9.4 2 3.8 46 86.8 
VOR 6 11.3 3 5.7 44 83 
AMB 0 0 2 3.8 51 96.2 
5-FC 53 100 0 0 0 0 
CASP 0 0 1 1.9 52 98.1 
  
µL 
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Proteolytic and biofilm activity
The data presented in Fig. (1A) showed that 8 out of  53 
isolates of  C. albicans (15%) have strong activity of  aspar-
tyl proteinase, 27 isolates have mild activity (51%), while 
18 isolates (34%) revealed no aspartyl proteinase activity.
The result of  biofilm formation shown in Fig. (1B) re-
vealed that 12 (22.6%) isolates out of  53 were strong bio-
film forming. Meanwhile, 1 (1.9%) isolate was moderate 
and 9 (17%) were weak biofilm producers. In addition, 31 
(58.5%) isolates were non-biofilm producers.
Genotypic detection of  Sap in C. albicans isolates us-
ing PCR
In the present study 53 isolates of  C. albicans in addition 
to standard Candida albicans strain (ATCC10231) were 
tested for the presence of  Sap9 and 10 genes. Sap9 gene 
was detected in 45 (84.9%) isolates, while Sap10 gene was 
detected in 42 (79.2%) isolates. Detection of  Sap9 and 
Sap10 genes in the PCR products of  Candida albicans iso-
lates on agarose gel at approximately 80 bp, as shown in 
figure (2).
 
Fig. (1): A: Phenotypic detection of secreted aspartyl protease activity in C. albicans isolates by culturing 
on bovine serum agar (BSA) agar and incubated at 28°C for 7 days and measuring the clearing zone 
around the growing colony, B: Detection of biofilm activity in C. albicans isolates after biofilm growth on 
microtiter plate containing Sabouraud broth (SDB) for 48 hours and measure the absorbance at 540 nm 
after staining with crystal violet. 
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The data presented in table (2) show that 5 isolates out of  
53 isolates were resistant to 3 anti-fungal which have pro-
teolytic activity with prevalence of  either Sap9 or Sap10 
genes or both; out of  these isolates 4 isolates show strong 
biofilm formation. The rest of  isolates (48 isolates) which 
were resistant to 2 or 1 anti-fungal drugs show strong 
biofilm formation in only 8 isolates (16%), while 30 iso-
lates have proteolytic activity (65%).
 
 
Fig. 2: Electrophoretic graph of conventional PCR products on 1.5% agarose gel stained with ethidium 
bromide in some represented C. albicans isolates (A: detection of Sap9 gene (80 bp amplicon), B: 
detection of Sap10 gene (80 bp amplicon). Lane 1 (M): represent 50 bp DNA ladder, Lane 2 (-C): negative 
control (reagent control mixture without DNA), Lane 3 (+C): positive control (reagent control mixture 
with DNA of standard strain ATCC 10231), Lane 4 to lane 15: clinical C. albicans isolates. DNA was 
extracted from Clinical C. albicans isolated from patients with systemic Candida albicans infections 
(respiratory tract, urinary tract infections and candidemia). 
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Table 2  
 









W + + + 5-FC 
1 R N + + + 5-FC 
2 R N - + + 5-FC 
3       14 R N - + + 5-FC 
15 R N + + + 5-FC 
16 R W - + + 5-FC 
17 R N - + + 5-FC 
18 R W + + + 5-FC 
19 R N + + + 5-FC 
20 R W - +        +             5-FC 
34 R N - - + 5-FC 
35 B N - + + 5-FC 
36 B S + + + 5-FC 
37 U W + + + 5-FC 
38 U S + + -  5-FC,   FLU, VOR 
39 U S + +  + 5-FC 
40 U M        +                        +        +              5-FC 
        41       U       S      +                  +             +                       5-FC 
42       U       S     +                  +          +                       5-FC 
43       U       W      -                  -           -                       5-FC 
44       U       S     +                  -           -                      5-FC 
45       U       S     +                 -           +                    5-FC 
46       U       S    ++ + + 5-FC 
47       U       N    ++                       + + 5-FC 
48       U       N     +                       + + 5-FC 
49       U       W     +                        - + 5-FC 
50       U       N     -                        + - 5-FC 
51       U       W     +                        - - 5-FC 
52       U       S   ++                        + + 5-FC 













W + + + 5-FC 
1 R N + + + 5-FC 
2 R N - + + 5-FC 
3 R N ++ + + 5-FC 
4 R S ++ + + 5-FC, FLU, VOR 
5 R N + - + 5-FC 
6 R N - - + 5-FC 
7 R N ++ + + 5-FC, FLU, VOR 
8 R N + + - 5-FC 
9 R N - + + 5-FC,  VOR 
10 R N + + + 5-FC 
11 B N ++ + + 5-FC 
12 R N - + + 5-FC 
13 R N - + + 5-FC 
14 R N - + + 5-FC 
15 R N + + + 5-FC 
16 R W - + + 5-FC 
17 R N - + + 5-FC 
18 R W + + + -FC
19 R N + + + 5-FC 
20 R W - + + 5-FC
21 B N + + + 5-FC 
22 R N - + + 5-FC 
23 R N - + + 5-FC 
24 B N + + + 5-FC 
25 R N - + + 5-FC 
26 R W + + + 5-FC 
27 R N + + + 5-FC 
28 R S ++ + - 5-FC, FLU, VOR 
29 R W - + - 5-FC 
30 B N + + - 5-FC 
31 R N + + - 5-FC 
32 R N - + - 5-FC 
33 R N + + + 5-FC 
34 R N - - + 5-  
35 B N - + + 5-FC 
36 B S + + + 5-FC 
37 U W + + + 5-FC 
38 U S + + - 5-FC, FLU, VOR 
39 U S + + + 5-FC 
40 U M + + + 5-FC 
41 U S + + + 5-FC 
42 U S + + + 5-FC 
43 U W - - - 5-FC 
44 U S + - - 5-FC 
45 U S + - + 5-FC 
46 U S ++ + + 5-FC 
47 U N ++ + + 5-FC 
48 U N + + + 5-FC 
49 U W + - + 5-FC 
50 U N - + - 5-FC 
51 U W + - - 5-FC 
52 U S ++ + + 5-FC 
53 U S + + + 5-FC, FLU, VOR 
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Discussion
The aim of  this work was to determine the relationship 
between the anti-fungal susceptibility in one side, and 
the biofilm formation as well as the secretion of  aspartic 
proteinases on the other side which represent major de-
terminants associated with the pathogenicity of  Candida 
species. 
The available therapies against fungal diseases are limited 
and classified into five classes that have different targets 
in the fungal cells; polyenes, azoles and allylamines target 
cell membrane, while pyrimidine analogs target the fungal 
DNA and RNA. In contrast the new class echinocandins 
target the fungal cell wall26. 
Prolonged usage of  azole anti-fungals in treating infec-
tions caused by C. albicans has led to the emergence of  
resistance. The acquisition of  azole resistance in clini-
cal isolates of  C. albicans generally results in Multi-Drug 
(MDR) Resistance27,28. 
The presence of  MDR in fungal pathogens is a serious 
complication during treatment of  opportunistic fungal 
infections and poses a vital threat to the present thera-
peutic regimes by limiting the number of  clinically useful 
anti-fungal drugs29. 
Biofilm formation in C. albicans has a major rule in patho-
genesis which allows Candida to adhere to mucosal cells 
and polymeric surfaces of  medical devices leading to 
spread of  nosocomial infections. Biofilm forming cells 
are characterized by a three-dimensional structure that 
can survive the immune system of  the host and associ-
ated with increasing the resistance to anti-fungal drugs30. 
The mechanism of  biofilm resistance to anti-microbial 
agents is not fully understood. One hypothesis supposed 
that the formation of  polysaccharide matrix has negative 
effect on the drugs penetration to fungal cells by forma-
tion of  strong barrier31, and only the outer layers are in 
contact with lethal doses of  anti-fungals5.
Interestingly, a correlation between anti-fungal suscep-
tibility and biofilm formation was observed in four out 
of  the five resistant clinical isolates in this work. These 
isolates were strong biofilm producers and revealed re-
sistant to 3 anti-fungal drugs which in agreement with 
that reported by Bitar et al.32, and Nobile and Mitchell33. 
They confirmed that the high resistance to fluconazole 
was usually associated with biofilm formation in C. albi-
cans isolates. This correlation could be explained based 
on many mechanisms including active extrusion by efflux 
pumps34. 
Severe candidiasis is correlated to the production of  ex-
tracellular hydrolytic enzymes which have a vital role in 
the pathogenesis of  the yeasts35,36. 
Aspartyl proteases are one of  the major virulence factors 
in C. albicans that reported to have a role in tissue invasion, 
hyphal formation, adherence, and phenotypic switching10. 
Many evidences prove the role of  Sap enzymes in patho-
genicity which include; the infected patients with C. albi-
cans have higher proteolytic activity than asymptomatic 
carriers, in the other hand, the HIV infected patients with 
C. albicans have high proteolytic activity10. Severe candidi-
asis is correlated to the production of  extracellular hydro-
lytic enzymes which have a vital role in the pathogenesis 
of  the yeasts35,36.
Furthermore a correlation between reduced susceptibility 
to anti-fungal agents and aspartyl proteinase production 
was confirmed in this study where all resistant isolates to 
the anti-fungals under investigations were aspartyl pro-
teinase producers. In addition 80% of  these isolates were 
biofilm producers. 
The current study revealed other correlation between 
prevalence of  Sap9 and Sap10 genes and the strong bio-
film producers by C. albicans isolates, as 66.7% of  these 
isolates have both Sap9 and Sap10, while 25% have either 
Sap9 or Sap10. One isolate (8.3%) has neither Sap9 nor 
Sap10. Previous result was consistent with that reported 
by Chaffin37 and Schild et al.17, in which the Sap9 and 
Sap10 mediate biofilm formation. Silva et al.38, proved 
that pathogenicity is related to biofilm formation which 
is a likely indicator of  growth, production of  hydrolytic 
enzymes as well as resistance to anti-microbial activity. 
Furthermore, Rajendran et al.39 found a correlation be-
tween higher SAP productions and increase the adhesion 
to buccal cells as well as resistance to fluconazole of  C. 
albicans isolates.
Another study made a correlation between the extracellu-
lar proteolytic activity in vitro and the virulence of  Can-
dida species and prove that only the most virulent species 
such as C. albicans, C. tropicalis and C. parapsilosis produce 
more proteinases in vitro than do less virulent species40. 
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Conclusion
Our study represents an advance in biomedical and health 
science by observing a link between the reduction in sus-
ceptibility to anti-fungal drugs and the virulence indicat-
ed by pathogenic C. albicans isolates mainly including the 
biofilm formation and Sap production. 
Disclosure statement




1. Bassetti M, Righi E, Montravers P, Cornely O. What 
has changed in the treatment of  invasive candidiasis? A 
look at the past 10 years and ahead. Journal of  Antimicrobial 
Chemotherapy.  2018; 73(1): i14-i25.
2. Lai CC, Wang CY, Liu WL, Huang WL, Hsueh PR. 
Time to positivity of  blood cultures of  different Candi-
da species causing fungaemia. Journal of  medical microbiology. 
2012; 61: 701–704.
3. Pfaller MA, Diekema DJ. Epidemiology of  invasive 
candidiasis: a persistent public health problem. Clinical 
Microbiology Reviews. 2007; 20(1): 133-163.
4. Odds FC, Gow NAR, Brown AJP. Toward a molecular 
understanding of  Candida albicans virulence. In: Heitman 
J, Filler SG, Edwards JE Jr, Mitchell AP (eds) Molecular 
principles of  fungal pathogenesis. Washington, DC, ASM 
Press; 2006;. 305–319. 
5. Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, 
Giannini MJS. Candida species: current epidemiology, 
pathogenicity, biofilm formation, natural antifungal prod-
ucts and new therapeutic options. Journal of  medical Micro-
biology. 2013; 62:10–24.
6. White TC, Agabian N. Candida albicans secreted aspartyl 
proteinases: isoenzyme pattern is determined by cell type, 
and levels are determined by environmental factors. Jour-
nal of  Bacteriology. 1995; 177:5215–5221.
7. Calderone RA, Gow NAR. Host recognition by Can-
dida species. In: Calderone R.A. (ed)  Candida and candi-
diasis. Washington: ASM Press; 2002.; 67–86. PubMed.
8. Calderoni RA, Fonzi WA. Virulence factors of  Candida 
albicans. Trends in Microbiology. 2001; 9: 327–335.
9. Schaller M, Schackert C, Korting HC, Januschke E, 
Hube, B. Invasion of  Candida albicans correlates with ex-
pression of  secreted aspartic proteinases during experi-
mental infection of  human epidermis. Journal of  Investiga-
tive Dermatology. 2000; 114:712–717.
10. Naglik   JR, Challacombe   SJ, Hube   B.    Candida albi-
cans secreted aspartyl proteinases in virulence and patho-
genesis. Microbiology and Molecular Biology Reviews. 2003 ; 
67:400 – 428.
11. Ray TL, Payne CD. Comparative production and 
rapid purification of  Candida acid proteinase from pro-
tein-supplemented cultures. Infection and Immunity. 1990; 
58: 508-514.
12. Parra-Ortega B, Cruz-Torres H, Villa-Tanaca L, 
Hernández-Rodríguez C. Phylogeny and evolution of  
the aspartyl protease family from clinically relevant Can-
dida species. Memórias do Instituto Oswaldo Cruz. 2009; 104: 
505–512.
13.   Sacristan B, Blanco MT, Galan-Ladero MA, Blanco J, 
Perez-Giraldo C, Gomez-Garcia AC. Aspartyl proteinase, 
phospholipase, hemolytic activities and biofilm produc-
tion of  Candida albicans isolated from bronchial aspirates 
of  ICU patients. Medical Mycology. 2011; 49(1): 94-97.  
14. Naglik   JR, Moyes   D, Markwana   J, Kanzaria P, Tsi-
chlaki E, Weindl G, et al.  Quantitative expression of  the 
Candida albicans secreted aspartyl proteinase gene family 
in human oral and vaginal candidiasis. Microbiology. 2008; 
154: 3266–3280. 
15. Nailis   H, Kucharikova   S, Ricicova   M, Van Dijck 
P, Deforce D, Nelis H, et al. Real-time PCR expression 
profiling of  genes encoding potential virulence factors in 
Candida albicans biofilms: identification of  model depen-
dent and independent gene expression.  BMC Microbiology. 
2010; 10: 114 .
16.  Mathe L, Van Dijck P. Recent insights into Candida 
albicans biofilm resistance mechanisms. Current Genetics. 
2013; 59:251–264.
17. Schild L, Heyken A, de Groot PW, Hiller E, Mock 
M, de Koster C, et al.  Proteolytic cleavage of  covalent-
ly linked cell wall proteins by Candida albicans Sap9 and 
Sap10.  Eukaryotic Cell.  2011; 10: 98–109.
18. Cheesbrough M. Microbiological Tests. In: Chees-
brough, M., Ed., District Laboratory Practice in Tropical 
Countries, Part II, Low Priced Edition, Cambridge, Cam-
bridge University Press; 2000; 105-130.
19. Kadry A, El-Ganiny A, El-Baz A. Comparison of  
methods used in identification of  Candida albicans. Re-
search Journal of  Pharmacy and Technology. (In press).
20. Clinical and Laboratory Standards Institute (CLSI). 
Method for anti-fungal disk diffusion susceptibility test-
ing of  yeasts: approved guideline, 2nd edition, Clinical 
and Laboratory Standards Instituite, Wayne, Pa 2009; 
M44-A2.
21. Al-Hedaithy SS. Spectrum and proteinase production 
African Health Sciences Vol 18 Issue 4, December, 2018 1173
of  yeast causing vaginitis in Saudi Arabian woman. Medi-
cal Science Monitor. 2002; 8: 498-501.
22.  Marinho SA, Teixeira AB, Santos OS, Cazanova RF, 
Ferreira CAS, Cherubini K, et al.  Identification of  candida 
spp. by phenotypic tests and PCR. Brazilian Journal of   Mi-
crobiology. 2010; 41: 286-294.
23. Monroy-Pérez E, Paniagua-Contreras G, Vaca-Pani-
agua F, Negrete-Abascal E, Vaca S. SAP Expression in 
Candida albicans Strains Isolated from Mexican Patients 
with Vaginal Candidosis. International Journal of  Medical 
Medicine. 2013; 4: 25-31.
24. Younes S, Bahnan W, Dimassi HI, Khalaf  RA. The 
Candida albicans Hwp2 is necessary for proper adhesion, 
biofilm formation and oxidative stress tolerance. Microbi-
ological Research. 2011; 166(5):430–436.
25.   Stepanovic´ S,   Vukovic´ D, Hola V, Di Bonaventura 
G, Djukic S, Cirkovic I, et al. Quantification of  biofilm 
in microtiter plates: overview of  testing conditions and 
practical recommendations for assessment of  biofilm 
production by Staphylococci. Journal of  Pathology, Microbiology 
and Immunology. 2007; 115: 891–899.
26.  Denning DW, Hope WW. Therapy for fungal dis-
eases: opportunities and priorities. Trends in Microbiology. 
2010; 18:195–204.
27.  White TC, Marr KA, Bowden RA. Clinical, cellular, 
and molecular factors that contribute to antifungal drug 
resistance. Clinical Microbiology Reviews. 1998; 11: 382-402.
28. Franz R, Ruhnke M, Morschhauser J. Molecular as-
pects of  fluconazole resistance development in Candida 
albicans. Mycoses. 1999; 42: 453-458. 
29. Cowen LE. The evolution of  fungal drug resistance: 
modulating the trajectory from genotype to phenotype. 
Nature Reviews Microbiology. 2008; 6: 187–198.
30.    Ingles DO, Skvzypek MS, Arnaudetal MB. Improved 
gene ontology annotation for biofilm form, filamentous 
growth, and phenotypic switching in Candida albicans.  Eu-
karyotic Cell. 2013; 12(1):101–108.
31. Kojic EM, Darouiche RO. Candida infections of  
medical devices. Clinical Microbiology Reviews. 2004; 17: 
255–267.
32. Bitar I, Khalaf  RA, Harastani H, Tokajian S. Iden-
tification, typing, antifungal resistance profile, and bio-
film formation of  Candida albicans isolates from Lebanese 
hospital patients. BioMed Research International.2014; 2014: 
931372, 10 pages.
33. Nobile CJ, Mitchell AP. Genetics and genomics of  
Candida albicans biofilm formation. Cellular Nicrobiology. 
2006; 8: 1382–1391.
34. Ramage G, Rajendran R, Sherry L, Williams C. Fungal 
biofilm resistance. International Journal of  Medical Microbiol-
ogy. 2012; 2012: 528521, 14 pages.
35. Bramono K, Yamazaki M, Tsuboi R, Ogawa H. Com-
parison of  proteinase, lipase and alpha-glucosidase activ-
ities from the clinical isolates of  Candida species. Japanese 
Journal of  Infectious Disease. 2006; 59:73–76.
36. Ingham CJ, Boonstra S, Levels S, de Lange M, Meis 
JF, Schneeberger PM. Rapid susceptibility testing and mi-
crocolony analysis of Candida spp. cultured and imaged on 
porous aluminum oxide. PLoS ONE. 2012; 7(3): e33818.
37. Chaffin   WL. Candida albicans cell wall proteins. Mi-
crobiology and Molecular Biology Reviews 2008; 72:495 
–544.
38. Silva S, Henriques M, Oliveira R, Williams D, Azeredo 
J. In Vitro Biofilm Activity of  Non-Candida albicans Candi-
da Species. Current Microbiology. 2010; 61:534–540. 
39. Rajendran R, Robertson DP, Hodge PJ, Lappin DF, 
Ramage G. Hydrolytic enzyme production is associated 
with Candida albicans biofilm formation from patients 
with type I diabetes. Mycopathologia. 2010; 70: 229–235. 
40. Ruchel R. Proteinase. In J. E. Bennett, R. J. Hay, and P. 
K. Peterson (ed.), New strategies in fungal disease. Chur-
chill Livingstone, Edinburgh, United Kingdom; 1992; 
17–31.
African Health Sciences Vol 18 Issue 4, December, 20181174
